Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 240Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE

The medical science liaison role in Spain: A nationwide survey


1 Medical Department, Amgen; MSL Profile Working Group, Medicine Association of the Pharmaceutical Industry, Spain
2 MSL Profile Working Group, Medicine Association of the Pharmaceutical Industry; MSL Medical Department, Chiesi España S.A, Barcelona, Spain
3 MSL Profile Working Group, Medicine Association of the Pharmaceutical Industry; Medical Affairs Department, Persan Farma, Las Palmas de Gran Canaria, AstraZeneca, Madrid, Spain
4 MSL Medical Department, AstraZeneca, Madrid, Spain

Correspondence Address:
Víctor Sastre,
World Trade Center, Moll de Barcelona S/N Edificio Sur 7ª Planta, 08039 Barcelona
Spain
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/picr.PICR_53_20

Context and Aims: The Medical Science Liaison's (MSL's) value to the company has evolved into a more strategic role with a wide variety of responsibilities. We conducted an online survey of current MSLs nationwide to assess their profile, activity development, performance evaluation, and career development. Subjects and Methods: A 37-item survey was hosted on SurveyMonkey© and accessible from December 2018 to February 2019. The survey was open to current MSLs from different pharmaceutical companies in Spain and included questions about the participant profile, activity development, performance evaluation, and career development. Statistical Analysis Used: The results were expressed as valid percentages; to establish relationships between the answers to different questions, exclusion and comparison filters were used on the web platform. Results: A total of 179 MSLs responded to the anonymous survey. Off-label information management (79%), relationships with key opinion leaders (76%), continuous medical training for HCPs (70%), involvement in clinical trials/investigator-initiated trials (68%), and elaboration of the National Strategy (67%) were mentioned as the top new competencies. Fifty-eight percent spend an average of 61%–80% of their time out in the field and 68% use remote interactions. Fifty-six percent did not agree that their current performance metrics are a reflection of their true value. Forty-five percent of the participants disagreed when asked if their activity is easily balanced with their personal lives. Conclusions: Based on our findings, we believe that there is a need to consider the MSL's strategic priorities, to define metrics that accurately assess MSL performance, and to find ways to fully maximize their limited time.
    
 

  Search Pubmed for
 
    -  Sastre V
    -  Matesanz-Marín A
    -  García C
    -  González del Castillo A
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1893    
    PDF Downloaded27    
    Cited by others 1    

Recommend this journal